Erythromycin Delays Symptom Recurrence.pdf

See discussions, stats, and author profiles for this publication at: /publicationLow-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on... Article in Gastroenterology and Hepatology · June 2009 Source: PubMed CITATIONS 12 READS 48 6 authors, including: Some of the authors of this publication are also working on these related projects: Microbiome in functional GI disorders and in NAFLD View project Mark Pimentel Cedars-Sinai Medical Center 243 PUBLICATIONS 5,197 CITATIONS SEE PROFILE Walter Morales Cedars-Sinai Medical Center 46 PUBLICATIONS 363 CITATIONS SEE PROFILE All content following this page was uploaded by Walter Morales on 21 May 2015. The user has requested enhancement of the downloaded file. All in-text references underlined in blue are added to the original document and are linked to publications on ResearchGate, letting you access and read them immediately. Gastroenterology Hepatology Volume 5, Issue 6 June 2009 435 Low-Dose Nocturnal Tegaserod or Erythromycin Delays Symptom Recurrence After Treatment of Irritable Bowel Syndrome Based on Presumed Bacterial Overgrowth Mark Pimentel, MD, FRCP(C), Walter Morales, Sheila Lezcano, Sun-Chuan Dai, MD, Kimberly Low, and Janet Yang, MD Dr. Pimentel serves as Director of the Gastro intestinal Motility Program at Cedars-Sinai Medical Center in Los Angeles, California. Mr. Morales, Ms. Lezcano, Dr. Dai, Ms. Low, and Dr. Yang are also affiliated with the Gastrointestinal Motility Program at Cedars-Sinai Medical Center. Address correspondence to: Dr. Mark Pimentel Director, GI Motility Program Cedars-Sinai Medical Center 8730 Alden Drive, Suite 225E Los Angeles, CA 90048; Tel: 310-423-6143; Fax: 310-423-8356; E-mail: mark.pimentel@ Keywords Irritable bowel syndrome, migrating motor complexes, small intestinal bacterial overgrowth, erythromycin, tegaserod Abstract: Our group previously demonstrated a deficiency o